![](/img/cover-not-exists.png)
A phase I clinical trial of low-dose interferon-α-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma
Robert J. Amato, Muhammad KhanVolume:
61
Language:
english
Pages:
5
DOI:
10.1007/s00280-007-0568-7
Date:
May, 2008
File:
PDF, 221 KB
english, 2008